Research programme: oncolytic virus therapies and diagnostics - Oncolys BioPharma

Drug Profile

Research programme: oncolytic virus therapies and diagnostics - Oncolys BioPharma

Alternative Names: hTERTp-Ad5; OBP 405; OBP 702; OBP-1101; OBP-401; Telomelysin-RGD; TelomeScan F35

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator National Institute of Biomedical Innovation; Okayama University
  • Developer Oncolys BioPharma
  • Class Oncolytic viruses
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 28 Mar 2017 Oncolys BioPharma and Osaka University agree to co-develop TelomeScan® for Solid tumours (Diagnosis)
  • 24 May 2016 Preclinical trials in Solid tumours (Diagnosis) in Japan (unspecified route) before May 2016 (Oncolys website, May 2016)
  • 20 May 2016 Oncolys and Wonik Cube agree to co-promote and co-develop OBP 1101 in Japan for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top